To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. TAR-200, an intravesical chemotherapy releasing ...

100% (n=7) of evaluable patients (1 CIS, 6 Ta/T1) achieved disease free status. One of these patients was re-treated at 3 months. “I am impressed by these promising NDV-01 data reported at AUA2025.

Relmada Therapeutics, Inc. announced the presentation of an abstract at the American Urology Association (AUA2025) conference in Las Vegas, highlighting a study on NDV-01, an investigational therapy ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

CG Oncology (NASDAQ:CGON), a biotech focused on non-muscle invasive bladder cancer (NMIBC), traded ~9% higher on Wednesday after Guggenheim launched its coverage with a Buy recommendation and a $90 ...

RARITAN, N.J., July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) ...

Please provide your email address to receive an email when new articles are posted on . A urinary DNA methylation test outperformed the nuclear matrix protein 22 test or urine cytology test.

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent 1 RARITAN, N.J., Jan. 15, 2025 ...

(Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a comprehensive review of the ...